Medtronic PLC

Medtronic’s new FDA‑cleared Hugo robotic system, MiniMed 780G launch, and Dr. Denny’s leadership boost show how the company is diversifying into surgery and diabetes, blending modular tech and data to stay ahead in regulated markets.

Medtronic PLC’s Q4 2025 earnings reveal how its expanding IoMT strategy fuels steady growth, positioning it ahead of rivals like GE Healthcare and Johnson & Johnson.

Medtronic PLC has navigated market turbulence through innovation and strategic expansion, with recent FDA approvals and market growth opportunities positioning the company for continued success in the health-care equipment and supply sector.

Medtronic PLC’s stock price target has been raised by analysts, driven by the company’s turnaround potential and growth catalysts in its cardiac ablation business.

Medtronic is set to release its quarterly earnings on August 19, 2025, with analysts predicting a 5.86% revenue increase and optimism surrounding the company’s prospects.

Medtronic PLC has reaffirmed its commitment to paying a consistent quarterly dividend of $0.71 per share, despite a cautious outlook from analysts.

Medtronic PLC has declared a consistent quarterly dividend and is working to drive growth, despite a recent analyst rating of ‘Hold’ ahead of earnings.

Medtronic has announced a cash dividend boost, lifting its yield to 3.1%, as the company seeks to revitalize growth and recover from a significant decline in its stock value since 2021.

Medtronic PLC’s stock price has declined by 33% since mid-2021, but the company is working to regain growth momentum through innovation and expansion into emerging markets.

Medtronic PLC has announced several developments, including a new Abbott sensor for its insulin delivery systems, and is poised for growth in the European defibrillator market due to rising cardiovascular disease cases and technological advancements.